Overview

A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy

Status:
Active, not recruiting

Trial end date:
2023-07-30

Target enrollment:

Participant gender:

Summary

The prognosis of patients with recurrent, late-stage inoperable, or progressed biliary tract carcinoma (BTC) is generally poor. The goal of this clinical study is to determine the effectiveness and safety of abemaciclib in patients with late-stage or progressed BTC that has failed one line of chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Milton S. Hershey Medical Center

Collaborator:

Eli Lilly and Company